Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis

References

• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment ofpsoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Bowcock AM, Kreuger JG. Getting under the skin: The immunogenetics of psoriasis. Nat Rev Immunol. 2005;5:699–711.
   PubMed Web of Science ®Google Scholar
• Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25:524–528.
   PubMed Web of Science ®Google Scholar
• Williams IR, Kupper TS. Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci. 1996;58:1485–1507.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564–569.
   PubMed Web of Science ®Google Scholar
• Meller S, Di Domizio J, Voo KS, et al. T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. Nat Immunol. 2015;16(9):970–979.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker JH. Psoriasis. N Engl J Med. 2009;361:496–509.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol. 2010;125:1261–1268.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873.
   PubMed Web of Science ®Google Scholar
• Fuentes-Duculan J, Suarez-Farinas M, Zaba LC, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol. 2010;130:2412–2422.
   PubMed Web of Science ®Google Scholar
• Korman NZ, Hao Y, Lu J, et al. Psoriasis disease severity affects patient satisfaction with treatment. Dermatol Online J. 2015;21(7):1.
   Google Scholar
• Saraceno R, Griffiths CE. A European perspective on the challenges of managing psoriasis. J Am Acad Dermatol. 2006;54:S81–4.
   PubMed Web of Science ®Google Scholar
• Warren RB, Griffiths CE. The future of biologic therapies. Semin Cutan Med Surg. 2010;29:63–66.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Gramiccia T, Saraceno S, et al. Apremilast for the treatment of psoriasis. Expert Opin Pharmacother. 2015;16(13):2083–2094.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Papp K. Apremilast in the treatment of psoriasis and psoriatic arthritis. Skin Therapy Lett. 2015;20(5):1–6.
   Google Scholar
• Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481–511.
   PubMed Web of Science ®Google Scholar
• Eigler A, Siegmund B, Emmerich U, et al. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol. 1998;63(1):101–107.
   PubMed Web of Science ®Google Scholar
• Serezani CH, Ballinger MN, Aronoff DM, et al. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39(2):127–132.
   PubMed Web of Science ®Google Scholar
• Zambon AC, Zhang L, Minovitsky S, et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci USA. 2005;102(24):8561–8566.
   PubMed Web of Science ®Google Scholar
• Ollivier V, Parry GC, Cobb RR, et al. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem. 1996;271(34):20828–20835.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Capone L, et al. is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–2029.
   PubMed Web of Science ®Google Scholar
• Aronoff DM, Carstens JK, Chen GH, et al. Short communication: differences between macrophages and dendritic cells in the cyclic AMP-dependent regulation of lipopolysaccharide-induced cytokine and chemokine synthesis. J Interferon Cytokine Res. 2006;26(11):827–833.
   PubMed Web of Science ®Google Scholar
• Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 2003;370(Pt 1):1–18.
   PubMed Web of Science ®Google Scholar
• Man HV, Schafer P, Wong LP, et al. Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-α inhibitor. J Med Chem. 2009;52:1522–1524.
   PubMed Web of Science ®Google Scholar
• Kodimuthali A, Jabaris SS, Pal M. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. J Med Chem. 2008;51:5471–5489.
   PubMed Web of Science ®Google Scholar
• Tenor H, Hatzelmann A, Beume R, et al. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. Handb Exp Pharmacol. 2011;204:85–119.
   PubMedGoogle Scholar
• Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83(1):113–118.
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10:1503–1519.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Strober B, Krueger JG, et al. An open label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24:1529–1538.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855.
   PubMed Web of Science ®Google Scholar
• Williams JJ, Palmer TM. Unbiased identification of substrates for the Epac1-inducible E3 ubiquitin ligase component SOCS-3. Biochem Soc Trans. 2012;40:215–218.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12(8):888–897.
   PubMed Web of Science ®Google Scholar
• Kowalczyk P, Kinjo T, Kowalczyk M, et al. Effect of phosphodiesterase antagonists on glucocorticoid mediated growth inhibition in murine skin cell lines. Eur J Pharmacol. 2009;610(1–3):29–36.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immuno Res. 2015;2015:906349.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105(S1):9–20.
   PubMedGoogle Scholar
• Abdulrahim H, Thistleton S, Adebajo AO, et al. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16(7):1099–1108.
   PubMed Web of Science ®Google Scholar
• Schett G, Sloan VS, Stevens RM, et al. Apremilast: A novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskeletal Dis. 2010;2:271–278.
   PubMedGoogle Scholar
• Hoffmann M I, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [(14)C] apremilast following oral administration. Xenobiotica. 2011;41(12):1063–1075.
   PubMed Web of Science ®Google Scholar
• Busa S, Kavanaugh A. Drug safety evaluation of apremilast for treating psoriatic arthritis. Expert Opin Drug Saf. 2015 Jun;14(6):979–985.
   PubMed Web of Science ®Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738–746.
   PubMed Web of Science ®Google Scholar
• Apremilast: Phase 2,3,4 - List Results. Bethesda (MD): US National Library of Medicine. Available from: www.ClinicalTrials.gov.
   Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized,controlled trial (ESTEEM 1) [oral]. Oral presented at: 71st Annual Meeting of the American Academy of Dermatology (AAD); 2013 Mar 1–5; Miami Beach, FL.
   Google Scholar
• Paul C, Cather J, Gooderham M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 2014 Mar 21–25, Denver, CO.
   Google Scholar
• Reich K, Sobell J, Day R, et al. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. Poster. Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20–24; San Francisco, CA.
   Google Scholar
• Papp KA, Reich K, Sobell JM, et al. Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a Phase 3, randomized, controlled trial (ESTEEM 1). Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20–24; San Francisco, CA.
   Google Scholar
• Available from: http://www.otezla.com/otezla-prescribing-information.pdf
   Google Scholar
• Papp K, Chen R, Day R, et al. Safety and tolerability of apremilast up to 182 weeks: pooled analyses from Phase 3 clinical trials. Abstract 2347, presented at the 74th American Academy of Dermatology 2016 annual conference; 2016 Mar 7; Washington, DC.
   Google Scholar
• Kavanaugh A, Adebajo AO, Gladman DD, et al. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a Phase III, randomized, controlled trial and open-label extension (PALACE 1). Presented at: the Summer Academy Meeting of the American Academy of Dermatology; 2015 Aug 19–23; New York, NY.
   Google Scholar
• Feldam SR, Tencer T, Clancy Z, et al. Cost per responder of apremilast versus etanercept, adalimumab, and stekinumab in patients with moderate to severe psoriasis. Poster. Presented at the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20–24; San Francisco, CA.
   Google Scholar
• Danesh MJ, Beroukhim K, Nguyen C, et al. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. Dermatol Online J. 2015;21(6):16.
   Google Scholar
• Papp K, Kaufmann R, Thaçi D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):376–383.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–181.
   PubMed Web of Science ®Google Scholar
• Schudt C, Winder S, Forderkunz S, et al. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol. 1991;344(6):682–690.
   PubMed Web of Science ®Google Scholar
• Ottaviani C, Nasorri F, Bedini C, et al. CD56 bright CD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol. 2006;36(1):118–128.
   PubMed Web of Science ®Google Scholar
• Brullo C, Massa M, Villa C, et al. Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors. Bioorg Med Chem. 2015;23(13):3426–3435.
   PubMed Web of Science ®Google Scholar
• Smith RL. Pediatric psoriasis treated with apremilast. JAAD Case Rep. 2016;2(1):89–91.
   PubMedGoogle Scholar